Key result
Endovascular treatment of right heart masses using the AngioVac system demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate.
Why the study?
Retrospective studies evaluating the AngioVac system remain limited, and outcome data for high-risk patients are also limited.
Does the AngioVac System provide safe and effective debulking or removal of right heart masses in critically ill patients?
Observational
No
Does the AngioVac System provide safe and effective debulking or removal of right heart masses in critically ill patients?
The AngioVac System provides a minimally invasive, highly successful option for the debulking or removal of right heart masses with 100% intraoperative survival, though bleeding and hemodynamic complications can occur.
May inform procedural planning in select high-risk cases; extends limited retrospective data but requires prospective validation.
OBJECTIVE: To describe our institution's experience with the AngioVac system. BACKGROUND: Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. With the advent of vacuum aspiration, more specifically the AngioVac System (AngioDynamics, NY, USA), there exists a system with both low mortality and minor complications. However, the number of retrospective studies remains limited. Outcome data for high-risk patients are also limited. METHODS: Data were collected and analyzed in patients who underwent AngioVac therapy at our tertiary care center from January 2014 to December 2020. RESULTS: Our results demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate. However, a number of complications, including but not limited to hematomas, anemia, and hypotension, occurred, as described below. CONCLUSIONS: Our experiences demonstrated good outcomes and continue to support the usefulness of the AngioVac System. The data also support the use of AngioVac as a treatment option for the debulking or removal of right heart masses in critically ill patients.
No takes yet. Share an insight, caveat, or question.
Katapadi et al. (2021) conducted an observational in Right heart masses. AngioVac System was evaluated on Intraoperative success rate. Endovascular treatment of right heart masses using the AngioVac system demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: